Welcome to our dedicated page for NEMAURA MEDICAL news (Ticker: NMRD), a resource for investors and traders seeking the latest updates and insights on NEMAURA MEDICAL stock.
Nemaura Medical Inc. (NMRD) is a pioneering medical technology company specializing in the discovery, development, and commercialization of diagnostic medical devices. Founded in 2009 and based in New York, New York, Nemaura Medical is committed to enhancing the healthcare industry with innovative solutions.
The company's flagship product is SugarBEAT, a non-invasive continuous glucose monitoring device designed for individuals with Type I and Type II diabetes, as well as those at risk of developing diabetes. SugarBEAT offers real-time glucose readings, helping users manage their health more effectively without the need for painful finger-pricking.
In addition to SugarBEAT, Nemaura Medical has entered a strategic license agreement with Healthimation, LLC. This agreement allows the company to offer an intensive medical diabetes and weight management program tailored for Type 2 diabetes, prediabetes, and general wellness. The program includes the innovative Why Wait app, which integrates licensed trademarks and provides users with a comprehensive health management tool.
The company prides itself on its strong partnerships and continuous advancements in medical technology. Recent projects and developments at Nemaura Medical reflect its dedication to improving patient outcomes and expanding its product portfolio.
For investors seeking timely updates and insights into Nemaura Medical's activities, the company regularly publishes news and financial summaries. Stay informed about the latest corporate highlights and innovations from Nemaura Medical by visiting their official website or contacting their investor relations team.
Nemaura Medical, Inc. (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will engage in a fireside chat on March 29, 2023, at 10 AM ET, hosted by EF Hutton's analyst Constantine Davides. The chat will explore Nemaura's innovative glucose monitoring device, digital health solutions, commercial strategy, and early patient data from their UK pilot program.
The company is developing non-invasive wearable sensors and has submitted a PMA for its sugarBEAT® device to the FDA. Nemaura aims to capitalize on a growing global diabetes market projected to reach nearly $59 billion by 2025.
Nemaura Medical (NASDAQ: NMRD) announced the inclusion of injectable insulin in its DuoPack Commercial License Agreement with MySugarWatch DuoPack Limited. This agreement allows Nemaura's non-invasive wearable sensors to be paired with insulin and other Type 2 diabetes medications, enhancing patient care through a holistic approach. The collaboration aims to provide access to a continuous glucose monitoring-guided insulin dosage system, potentially reducing hospital admissions and improving outcomes for approximately 4 million older diabetes patients in the UK and EU. Nemaura continues to innovate in the diabetes management market, expected to exceed $59 billion by 2025.
FAQ
What is the current stock price of NEMAURA MEDICAL (NMRD)?
What is the market cap of NEMAURA MEDICAL (NMRD)?
What is Nemaura Medical Inc.?
What products does Nemaura Medical Inc. offer?
Where is Nemaura Medical Inc. based?
When was Nemaura Medical Inc. founded?
What is SugarBEAT?
How does SugarBEAT help diabetic patients?
What is the Why Wait app?
Who are Nemaura Medical's partners?
Where can I find more information about Nemaura Medical Inc.?
How can investors stay updated on Nemaura Medical Inc.'s activities?
